16:46:48 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
PCI Biotech Holding är en biofarmaceutiskt koncern, där största delen av verksamheten bedrivs inom dotterbolaget PCI Biotech. Koncernen bedriver idag verksamhet inom utveckling av terapeutiska produkter baserat på den egenutvecklade PCI tekniken. Lösningarna är avsedda att användas vid behandling utav cancerpatienter. PCI Biotech grundades ursprungligen 2000 som ett dotterbolag till Photocure och har idag sitt huvudkontor i Oslo.

Kalender

2022-11-23 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-25 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning PCIB 0.00 NOK
2021-05-28 Årsstämma 2021
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning PCIB 0.00 NOK
2020-05-27 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning PCIB 0.00 NOK
2019-05-29 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning PCIB 0.00 NOK
2018-05-29 Årsstämma 2018
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-19 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-05-30 Ordinarie utdelning PCIB 0.00 NOK
2017-05-29 Årsstämma 2017
2017-05-16 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-12-08 Extra Bolagsstämma 2016
2016-11-22 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-05-20 Ordinarie utdelning PCIB 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-03 Kvartalsrapport 2016-Q1
2016-02-09 Bokslutskommuniké 2015
2015-11-17 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning PCIB 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-12 Kvartalsrapport 2015-Q1
2015-02-24 Bokslutskommuniké 2014
2014-11-18 Kvartalsrapport 2014-Q3
2014-08-19 Kvartalsrapport 2014-Q2
2014-05-14 Ordinarie utdelning
2014-05-13 Årsstämma 2014
2014-05-13 Kvartalsrapport 2014-Q1
2014-02-25 Bokslutskommuniké 2013
2013-10-29 Kvartalsrapport 2013-Q3
2013-08-20 Kvartalsrapport 2013-Q2
2013-05-07 Ordinarie utdelning
2013-05-06 Årsstämma 2013
2013-04-30 Kvartalsrapport 2013-Q1
2013-03-21 Bokslutskommuniké 2012
2012-10-30 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-08 Kvartalsrapport 2012-Q1
2012-04-26 Ordinarie utdelning
2012-04-25 Årsstämma 2012
2012-02-07 Bokslutskommuniké 2011
2011-11-01 Kvartalsrapport 2011-Q3
2011-08-23 Kvartalsrapport 2011-Q2
2011-05-10 Kvartalsrapport 2011-Q1
2011-04-14 Ordinarie utdelning
2010-10-25 Kvartalsrapport 2010-Q3
2010-08-23 Kvartalsrapport 2010-Q2
2010-05-19 Ordinarie utdelning
2010-05-18 Årsstämma 2010
2010-04-26 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-10-26 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-29 Kvartalsrapport 2009-Q1
2020-10-06 15:01:43
Oslo, 06 October 2020

In  accordance with the authorisation granted  by the Annual General Meeting 27
May  2020, the Board of Directors of PCI Biotech Holding ASA has awarded a total
of  540,000 share options to key employees. Each share option gives the right to
subscribe  for or acquire one share per  option (after PCI Biotech Holding ASA's
choice),  at a strike price  of NOK 50.36, equal to  the volume weighted average
share price (VWAP) for the last 5 days of trade prior to the grant date.

The  share options can be exercised  with 1/3 of the options after approximately
one  year, further  1/3 after approximately  two years  and the last third after
approximately   three   years.  To  ensure  long  term  ownership  by  executive
management, shares shall be held for at least three years after exercise, except
shares  to be  sold immediately  to cover  transaction costs  and tax under a so
called  cash less  exercise. The  share options  are subject  to other customary
terms  and conditions for employee incentive  programs and the share options are
lapsing in Q3 2025.

Of  the  540,000 share  options,  400,000 share  options  were  allotted  to the
following primary insiders:
90,000 share  options were  allotted to  Amir Snapir,  CMO. After the allotment,
Amir  Snapir holds a total portfolio  of 90,000 unexercised share options and 0
shares.
90,000 share  options were allotted to Ludovic  Robin, CBO. After the allotment,
Ludovic Robin holds a total portfolio of 90,000 unexercised share options and 0
shares.
70,000 share  options were allotted to Per Walday, CEO. After the allotment, Per
Walday  holds a total portfolio of 225,000 unexercised share options and 72,700
shares.
50,000 share  options were allotted to Anders  Høgset, CSO. After the allotment,
Anders  Høgset holds a total portfolio  of 150,000 unexercised share options and
64,800 shares.
50,000 share options were allotted to Ronny Skuggedal, CFO. After the allotment,
Ronny Skuggedal holds a total portfolio of 140,000 unexercised share options and
55,000 shares.
50,000 share  options were  allotted to  Lucy Wabakken,  CDO (acting). After the
allotment,  Lucy Wabakken holds  a total portfolio  of 120,000 unexercised share
options and 0 shares. Her related parties holds 10,008 shares.

The  current authorisation, as of 27 may  2020, allows for a total of 2,790,000
share  options,  of  which  1,245,500 now  have  been  granted  by  the Board of
Directors.

For more information, please contact:
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

This  information is subject to the disclosure requirements pursuant to sections
5-12 and 4-2 of the Norwegian Securities Trading Act.